The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Eli Lilly and Co. has begun selling its blockbuster weight-loss and diabetes drug Mounjaro in India, pipping rivals in a ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly and Novo Nordisk have scored big wins from the FDA in recent months, as the agency cracks down on copycat versions ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Eli Lilly launches anti-obesity and diabetes drug Mounjaro in India, priced competitively at Rs 14,000-17,500, a fraction of ...

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India after receiving regulatory approval. With rising ...

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a ...

Eli Lilly launches Mounjaro in India, targeting the $150B weight-loss market. The GLP-1 drug offers diabetes control & major ...